Small cell lung cancer (SCLC) is an exceptionally lethal malignancy for which more effective
therapies are urgently needed. Several lines of evidence, from SCLC primary human …

Small cell lung cancer (SCLC) is an aggressive malignancy characterized by rapid growth,
early metastasis, and acquired therapeutic resistance. A majority of patients with SCLC have …

Purpose: The classification of small cell lung cancer (SCLC) into distinct molecular subtypes
defined by ASCL1, NEUROD1, POU2F3, or YAP1 (SCLC-A,-N,-P, or-Y) expression, paves …

Small cell lung cancer (SCLC) is an extremely aggressive neuroendocrine tumor,
accounting for approximated 13% of all lung cancer cases. SCLC is characterized by rapid …

The tissue distribution and prognostic relevance of subtype‐specific proteins (ASCL1,
NEUROD1, POU2F3, YAP1) present an evolving area of research in small‐cell lung cancer …

Small cell lung cancer (SCLC) is a neuroendocrine tumor treated clinically as a single
disease with poor outcomes. Distinct SCLC molecular subtypes have been defined based …

Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined
by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A,-N, and-P …

Small cell lung cancer (SCLC; accounting for approximately 13%–15% of all lung cancers)
is an exceptionally lethal malignancy characterized by rapid doubling time and high …

Despite molecular and clinical heterogeneity, small cell lung cancer (SCLC) is treated as a
single entity with predictably poor results. Using tumor expression data and non-negative …

Molecular subtypes of small cell lung cancer (SCLC) defined by the expression of key
transcription regulators have recently been proposed in cell lines and limited number of …